Cover Image
市場調查報告書

全球自動注射器市場 (2016-2026年)

Global Autoinjectors Market, 2016 - 2026

出版商 ROOTS ANALYSIS 商品編碼 358442
出版日期 內容資訊 英文 380 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球自動注射器市場 (2016-2026年) Global Autoinjectors Market, 2016 - 2026
出版日期: 2016年05月11日 內容資訊: 英文 380 Pages
簡介

由於自行投藥的容易度和患者配合度的提高,對投藥的不安和削減錯誤等各種優點,自動注射器獲得醫藥品企業及終端用戶雙方很大的歡迎。還有對針插事故等安全性的擔憂擴大,也成為推動該產品的市場成長的要素。

本報告提供全球自動注射器的市場調查,市場及產品概要,目前市場環境,開發平台趨勢,主要的產品的案例研究,主要經營者及新興經營者簡介產品系列,各疾病/藥物區分、地區、產品區分、用途的市場規模的變化與預測,專家的見解,未來的成長機會、展望等彙整資料。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 藥物輸送用的各種設備
  • 使用針頭注射器的傳統非口服投藥
  • 自行投藥:新的趨勢
  • 自行注射器的各種類型
  • 自行注射器的市場
  • 針插事故
  • 自動注射器:自行注射器的重要種類
  • 法律規章相關考察
  • 藥物、設備的組合產品

第4章 自動注射器的主要藥物容器

  • 本章概要
  • 主要藥物容器
    • 瓶子
    • 預填充式注射器

第5章 自動注射器:目前市場環境

  • 本章概要
  • 自動注射器:整體市場概要
    • 各企業
    • 各主要藥物容器類型
    • 各實用性
    • 各用法
    • 各給藥途徑
  • 已通過核准組合產品:整體市場概要
    • 各企業
    • 各適應症
    • 各主要藥物容器類型
    • 各實用性
    • 各給藥途徑
    • 各標靶藥物
  • 開發平台組合產品:整體市場概要
  • 產品的競爭力分析
    • 拋棄式自動注射器
    • 半拋棄式/可重複使用的自動注射器

第6章 案例研究

  • 本章概要
  • 可利用自動注射器或評估中的藥物
  • 案例研究I:腎上腺素/腎上腺素
  • 案例研究II:Interferon betas1a/1b (多發性硬化症)
  • 可能成為自動注射器的對象的標的
    • 已上市分子
    • 開發平台分子

第7章 主要企業

  • 本章概要
  • Bespak
  • Changzhou Delfu Technology
  • DALI Medical Devices
  • Elcam Medical
  • Meridian Medical Technologies
  • Owen Mumford
  • Scandinavian Health Limited (SHL) Group
  • Union Medico
  • Ypsomed
    • 企業概要
    • 財務趨勢
    • 產品系列
    • 近幾年的發展趨勢
    • 未來展望等

第8章 新興企業

  • 本章概要
  • Amedra Pharmaceuticals (Impax Laboratories)
  • Kaleo Pharma
  • Nuance Designs
  • Oval Medical Technologies
  • Xeris Pharmaceuticals
  • Zion Clinical Pharmacy
    • 企業概要
    • 產品系列

第9章 全球自動注射器市場預測

  • 本章概要
  • 調查範圍、調查手法
  • 整體市場規模、預測
    • 各地區
    • 拋棄式
    • 可重複使用
    • 皮下注射用
    • 肌肉注射用
  • 市場規模、預測:過敏性反應
    • 拋棄式
    • 可重複使用
    • 皮下注射用
    • 肌肉注射用
  • 市場規模、預測:多發性硬化症
    • 拋棄式
    • 可重複使用
    • 皮下注射用
    • 肌肉注射用
  • 市場規模、預測:類風濕性關節炎
    • 拋棄式
    • 可重複使用
    • 皮下注射用
    • 肌肉注射用
  • 市場規模、預測:偏頭痛
    • 拋棄式
    • 可重複使用
    • 皮下注射用
    • 肌肉注射用
  • 市場規模、預測:糖尿病
    • 拋棄式
    • 可重複使用
    • 皮下注射用
    • 肌肉注射用
  • 市場規模、預測:其他
    • 拋棄式
    • 可重複使用
    • 皮下注射用
    • 肌肉注射用

第10章 未來的成長機會

  • 本章概要
  • 生命週期管理
  • 生物製藥、生技仿製藥的開發平台的擴大
  • 成為自動注射器新標的之適應症
  • 擴張/引進到新興地區
  • 特定的成長口袋

第11章 專家的採訪

第12章 總論

第13章 附錄1:圖表

第14章 附錄2:企業、機關清單

圖表

目錄
Product Code: RA10059

With the rising trend towards self-injection devices and rapidly growing pipeline of the biologics / biosimilars, autoinjectors have recently emerged as an important class of medical devices. Compared to conventional delivery systems, these devices automate the process of delivering drugs through subcutaneous or intramuscular routes. Autoinjectors are primarily spring-driven systems and use fillable / prefilled syringes or cartridges as primary containers. Due to their numerous benefits including easy self-administration, improved patient compliance, reduced anxiety and dosage errors, these devices have gained a lot of popularity from both pharmaceutical companies and end-users. The growing concern about the hazards associated with the needlestick injuries and other safety concerns has given an additional push to the market.

The origin of autoinjectors dates back to 1960s when a self-administered device was developed with a primary motive for use in military purposes to inject the antidote for nerve agents in biological weapons. Subsequently, EpiPen® by Pfizer / Mylan became the first disposable autoinjector to hit the US commercial market and received marketing approval in 1980s for the treatment of anaphylaxis. Following this, several autoinjectors were approved for various therapeutic indications. Anaphylaxis, so far, has continued to dominate the overall market. Autoinjectors for other chronic / emergency indications such as multiple sclerosis, rheumatoid arthritis, migraine, psoriasis and diabetes have also witnessed rising adoption.

It is well-known that pharmaceutical companies have frequently collaborated with device manufacturing companies to develop innovative drug delivery systems for their respective marketed / pipeline drugs. Several drugs have been approved in combination with autoinjectors in the past few years. Examples of such drugs include SIMPONI®, AVONEX®, PLEGRIDY®, EVZIO®, Repatha™, ORENCIA®, Trulicity®, ACTEMRA®, Otrexup™, Cosentyx® and COPAXONE®. In addition, these devices act as a life cycle management tool for drugs for which the patent has already expired or is close to expiry.

The increased interest has driven medical device manufacturers to introduce next generation of autoinjectors with advanced features and innovative designs making drug administration relatively more safe and convenient. Reformulation of first generation biologics, growing prevalence of chronic diseases, urgent treatment required in emergency conditions, needle safety regulations and technological advancements in this area are some of the factors that will drive this market in the near future.

Synopsis:

The ‘Global Autoinjectors Market, 2016-2026' report provides a comprehensive analysis of the current state of autoinjectors market and the likely future evolution of these devices over the next decade. Starting with an overview of self-administration devices, the report elaborates on the origin / history of autoinjectors, their components and advantages offered by different categories of autoinjectors. It also covers information on needlestick injuries and looks at the safety laws and legislations across major regional markets for prefilled syringes that are incorporated as primary drug containers in autoinjectors.

One of the key objectives of the study is to enumerate various autoinjectors available in the market, combination products currently available / being developed and the corresponding market potential across different therapeutic areas. Amongst other elements, the report elaborates on the following key areas:

  • The current state of the market with respect to key players, routes of administration, primary drug containers, usability, indications and drugs being targeted.
  • 2 X 2 matrices depicting the product competitiveness and supplier power across the growing landscape of disposable and reusable autoinjectors.
  • Detailed case studies on the drugs that have been potential targets for autoinjectors.
  • List of likely candidates for delivery via autoinjectors based upon their route of administration, targeted indication and dosage regime.
  • Detailed company profiles of the key autoinjector manufacturers as well as emerging players that are trying to build a foothold in this industry.
  • The future growth opportunities likely to drive the market in the short term and long term.

The study also focuses on analyzing the existing market size and potential future growth of these drug delivery devices across different therapeutic classes, routes of administration and extent of usability. The report provides sales forecast for the overall autoinjectors market for the period 2016 - 2026. It takes into account the price variation that is likely to occur as a result of mass adoption and increased competition. For the purposes of the study, we interviewed important stakeholders to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. 2015 is the base year; actual figures have been sourced and analyzed from publicly available information. Unless otherwise specified, all figures are presented in USD.

Example Highlights:

  • 1. During our research, we identified over 80 autoinjectors being developed or commercially available by more than 20 companies. Over 50 drugs as combination products have been commercialized so far; several companies such as Amgen, GSK, Sanofi and Palatin Technologies are testing their late stage pipeline drugs with autoinjectors.
  • 2. Most of the autoinjectors being developed are disposable devices, contributing a share of 62%; reusable / rechargeable / electronic autoinjectors have also emerged providing options for multiple dosing of the drugs.
  • 3. Some of the established pharmaceutical stakeholders working in this domain include BD, Bespak, Changzhou Delfu, Elcam Medical, DALI Medical Devices, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico, West Pharmaceutical Services and Ypsomed. Several new / small companies have entered with their innovative technologies and devices. Examples of such innovators include Amedra Pharmaceuticals, ChemProtect SK, Future Injection Technologies, Haselmeier AG, Kaleo Pharma, Nuance, Nemera, Oval Medical Technologies, Unilife and Xeris Pharmaceuticals.
  • 4. Developers are focusing on introducing a variety of advanced features to make these devices more user-friendly. Specific examples include push-on-skin release, one-handed operation, twist & mix mechanism, automatic reconstitution / priming, anti-roll, compact and sleek designs. Smart electronic autoinjectors are being developed featuring bluetooth connectivity, LCD screen and special software to connect the device or part of the device with computer systems to maintain injection records. Some of the devices, such as Safelia™ autoinjector (Nemera) and Syrina™ AR (Bespak), are also capable of delivering drugs with high volume and high viscosity.
  • 5. A variety of novel technologies have emerged for the development of autoinjectors. Examples of such technologies include Breeze™ technology (Nuance Designs), Depot Control technology (Union Medico), VapourSoft™ technology (Bespak), Rotaject™ Pressure Release technology, NIT™ technology, Negasai™ spring technology and Pushclick™ technology (SHL Group).
  • 6. Although autoinjectors have been in the market for over two decades, the market is still evolving. There is widespread optimism that such devices hold significant opportunity for the pharmaceutical companies; the rapidly evolving pipeline of biologics and biosimilars will act as a major driver.
  • 7. We anticipate the global autoinjectors market to grow at an annualized growth rate of over 8% in the next ten years. Launch in emerging regions such as India and China, availability of such devices for other chronic (in addition to multiple sclerosis and rheumatoid arthritis) and emergency indications (in addition to anaphylaxis), introduction of life cycle management projects for drugs nearing patent expiry are some of the opportunity areas wherein the companies are likely to focus on.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of autoinjectors market.

Chapter 3 provides a general overview of the various self-injection devices and autoinjectors. It covers the historical evolution of autoinjectors, their components, categories and associated manufacturing/packaging processes. In addition, it elaborates on the benefits of autoinjectors that have led to a growing adoption over the last several years. The chapter also highlights the issue of needlestick injuries and various preventive laws worldwide that have put the focus on introducing safety features in these devices.

Chapter 4 includes an introduction on the types of primary drug containers that are utilized in autoinjectors. Broadly, it covers an overview on the current trends coming up in the market of prefilled syringes and cartridges. It also lists the key manufacturers of these primary drug containers.

Chapter 5 provides a comprehensive analysis of the current market of autoinjectors. It lists over 80 autoinjector devices (including variants) that can be used to carry out self-administration for a variety of application areas. For these devices, we have identified the type and volume of the primary drug container used, usability, route of administration, needle size and other technical parameters. The chapter also includes list of combination products that have been approved or are under development with respect to indications being targeted. For both disposable and reusable autoinjectors, we have presented 2 X 2 matrices to compare the relevant product competitiveness and supplier power.

Chapter 6 presents a list of therapeutic drugs that are currently available in autoinjectors. It also provides case studies on the most common drugs / indications targeted. In addition, we have put together a list of potential molecules, based upon the route of administration, indication targeted and dosage regime, which are likely to form the target drugs for delivery via autoinjectors in the future.

Chapter 7 provides detailed profiles of key autoinjector manufacturers highlighting information on the company overview, financial performance, technology overview, product portfolio, collaborations and recent developments. Key players covered in this section include (in alphabetical order) Bespak, DALI Medical Devices, Elcam Medical, Meridian Medical Technologies, Owen Mumford, SHL Group, Union Medico and Ypsomed Delivery Systems.

Chapter 8 discusses profiles of new entrants in the autoinjectors industry. These profiles cover information on their company overview, technology overview, product portfolio and recent developments. Emerging players covered in this section include (in alphabetical order) Amedra Pharmaceuticals, Kaleo Pharma, Nuance Design, Oval Medical Technologies, Xeris Pharmaceuticals and Zion Clinical Pharmacy.

Chapter 9 provides a detailed description of the likely evolution of autoinjectors market. We have adopted a ‘top down' approach, backed by robust data and credible inputs from primary research, to identify the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 10 highlights the key future growth opportunities likely to increase market share of manufacturers active in this area. These include life cycle management, growing pipeline of biologics and biosimilars, emerging target indications, launch of autoinjectors in other regions and introduction of specific advanced and user friendly features in these devices.

Chapter 11 is a collection of interview transcripts. For the purpose of our study, we contacted number of stakeholders in order to ascertain the key strategic initiatives and future roadmap of the industry. These include Douglas Marenzi (Managing Director, PHC) and Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical). Other participants requested anonymity.

Chapter 12 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which provides a list of companies and organizations mentioned in this report.

Table of Contents

1. Preface

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. Executive Summary

3. Introduction

  • 3.1. Chapter Overview
  • 3.2. Drug Delivery Devices
  • 3.3. Conventional Parenteral Delivery Using a Needle and Syringe
  • 3.4. Self-Administration: An Emerging Trend
    • 3.4.1. Rising Burden of Chronic Diseases
    • 3.4.2. Need for Immediate Treatment in Emergency Situations
    • 3.4.3. Expansion of Injectable Biologic Products
  • 3.5. Types of Self- Injection Devices
    • 3.5.1. Prefilled Syringes
    • 3.5.2. Pen-Injectors
    • 3.5.3. Needle-Free Injectors
    • 3.5.4. Autoinjectors
    • 3.5.5. Large Volume Wearable Injectors
  • 3.6. Self-Injection Devices Market
  • 3.7. Needlestick Injuries
    • 3.7.1. Incidence And Cost Burden
    • 3.7.2. Prevention
    • 3.7.3. Government Legislation for the Prevention of Needlestick Injuries
    • 3.7.4. Safety Options in Self-Injectors
  • 3.8. Autoinjectors: An Important Class of Self-Injection Devices
    • 3.8.1. Components of Autoinjectors
    • 3.8.2. Classification of Autoinjectors
      • 3.8.2.1. On the Basis of Mechanism
      • 3.8.2.2. On the Basis of Usability
      • 3.8.2.3. On the Basis of Dose Delivered
    • 3.8.3. Manufacturing/Packaging
    • 3.8.4. Benefits of Autoinjectors
  • 3.9. Regulatory Considerations
  • 3.10. Drug Device Combination Products

4. Primary Drug Containers in Autoinjectors

  • 4.1. Chapter Overview
  • 4.2. Primary Drug Container
    • 4.2.1. Vials
    • 4.2.2. Cartridges
      • 4.2.2.1. Components of Cartridges
      • 4.2.2.2. Glass: Historical Material of Choice
      • 4.2.2.3. Types of Cartridges
        • 4.2.2.3.1. Single Chamber Cartridge
        • 4.2.2.3.2. Dual Chamber Cartridge
      • 4.2.2.4. Applications of Cartridges
      • 4.2.2.5. Drawbacks of Cartridges
      • 4.2.2.6. Companies Developing Cartridges
    • 4.2.3. Prefilled Syringes
      • 4.2.3.1. Components of Prefilled Syringes
      • 4.2.3.2. Classification of Prefilled Syringes
        • 4.2.3.2.1. Based on Barrel Material
        • 4.2.3.2.2. Based on Number of Chambers
        • 4.2.3.2.3. Based on Type of Needle
      • 4.2.3.3. Prefilled Syringes: Key Benefits
        • 4.2.3.3.1. Benefits over Traditional Injectable Devices
        • 4.2.3.3.2. Benefits for Healthcare Professionals and End Users
        • 4.2.3.3.3. Benefits for Manufacturers
      • 4.2.3.4. Advantages of Plastic Prefilled Syringes
      • 4.2.3.5. Prefilled Syringe Systems Available in the Market
        • 4.2.3.5.1. Glass Prefilled Syringes
        • 4.2.3.5.2. Plastic Prefilled Syringes

5. Autoinjectors: Current Market Landscape

  • 5.1. Chapter Overview
  • 5.2. Autoinjectors: Overall Market Overview
    • 5.2.1. Autoinjectors: Distribution by Players
    • 5.2.2. Autoinjectors: Distribution by Type of Primary Drug Container
    • 5.2.3. Autoinjectors: Distribution by Usability
    • 5.2.4. Autoinjectors: Distribution by Type of Dosage
    • 5.2.5. Autoinjectors: Distribution by Route of Administration
  • 5.3. Approved Combination Products: Overall Market Overview
    • 5.3.1. Approved Combination Products: Distribution by Players
    • 5.3.2. Approved Combination Products: Distribution by Target Indication
    • 5.3.3. Approved Combination Products: Distribution by Type of Primary Drug Container
    • 5.3.4. Approved Combination Products: Distribution by Usability
    • 5.3.5. Approved Combination Products: Distribution by Route of Administration
    • 5.3.6. Approved Combination Products: Distribution by Target Drug
  • 5.4. Pipeline Combination Products: Overall Market Overview
  • 5.5. Product Competitiveness Analysis
    • 5.5.1. Product Competitiveness Analysis for Disposable Autoinjectors
    • 5.5.2. Product Competitiveness Analysis for Semi-Disposable/ Reusable Autoinjectors

6. Case Studies

  • 6.1. Chapter Overview
  • 6.2. Drugs Available / Being Evaluated With Autoinjectors
  • 6.3. Case Study I: Adrenaline/Epinephrine
    • 6.3.1. Overview
    • 6.3.2. Mechanism of Action
    • 6.3.3. Anaphylaxis: Overview and Epidemiology
    • 6.3.4. History of Development
    • 6.3.5. Adrenaline/ Epinephrine Autoinjectors
      • 6.3.5.1. Marketed Adrenaline/ Epinephrine Autoinjectors
        • 6.3.5.1.1. Adrenaclick®
        • 6.3.5.1.2. Allerject / Auvi-Q® (Formerly called e-cue™)
        • 6.3.5.1.3. Anapen®
        • 6.3.5.1.4. Emerade®
        • 6.3.5.1.5. EpiPen®
        • 6.3.5.1.6. Jext®
      • 6.3.5.2. Adrenaline/ Epinephrine Autoinjectors Under Development
        • 6.3.5.2.1. Oval Autoinjector
        • 6.3.5.2.2. Abiliject
    • 6.3.6. Other Dosage Forms
    • 6.3.7. Historical Sales
  • 6.4. Case Study II: Interferon beta-1a/ Interferon beta-1b (Multiple Sclerosis)
    • 6.4.1. Overview
      • 6.4.1.1. Interferon beta-1a
      • 6.4.1.2. Interferon beta-1b
    • 6.4.2. Mechanism of Action
    • 6.4.3. Multiple Sclerosis: Overview and Epidemiology
    • 6.4.4. History of Development
    • 6.4.5. Interferon-beta Autoinjectors
      • 6.4.5.1. Interferon beta-1a Autoinjectors
        • 6.4.5.1.1. Avonex Pen®
        • 6.4.5.1.2. PLEGRIDY Pen
        • 6.4.5.1.3. Rebif ® Rebidose ®
        • 6.4.5.1.4. RebiSmart™
        • 6.4.5.1.5. Rebiject II®
      • 6.4.5.2. Interferon beta-1b Autoinjectors
        • 6.4.5.2.1. BETACONNECT™
        • 6.4.5.2.2. BETAJECT® Comfort/ Betacomfort®
        • 6.4.5.2.3. Betaject® Lite
        • 6.4.5.2.4. ExtaviJect® 30G/ ExtaviPro® 30G
    • 6.4.6. Other Dosage Forms
    • 6.4.7. Historical Sales
      • 6.4.7.1. Interferon beta-1a
      • 6.4.7.2. Interferon beta-1b
  • 6.5. Likely Targets for Autoinjectors
    • 6.5.1. Marketed Molecules
      • 6.5.1.1. Marketed Molecules: Most Likely Candidates for Autoinjectors
      • 6.5.1.2. Marketed Molecules: Likely Candidates for Autoinjectors
      • 6.5.1.3. Marketed Molecules: Less Likely Candidates for Autoinjectors
    • 6.5.2. Pipeline Molecules
      • 6.5.2.1. Pipeline Molecules: Most Likely Candidates for Autoinjectors
      • 6.5.2.2. Pipeline Molecules: Likely Candidates for Autoinjectors
      • 6.5.2.3. Pipeline Molecules: Less Likely Candidates for Autoinjectors

7. Key Players

  • 7.1. Chapter Overview
  • 7.2. Bespak
    • 7.2.1. Company Overview
    • 7.2.2. Financial Performance
    • 7.2.3. Technology Overview
    • 7.2.4. Product Portfolio
      • 7.2.4.1. Autoinjectors
        • 7.2.4.1.1. Syrina™
        • 7.2.4.1.2. ASI™ Autoinjector
        • 7.2.4.1.3. OTS™ Autoinjector
    • 7.2.5. Recent Developments
      • 7.2.5.1. Collaborations
        • 7.2.5.1.1. Aesica Pharmaceuticals
        • 7.2.5.1.2. Undisclosed Global Generic Company
        • 7.2.5.1.3. Undisclosed Global Pharmaceutical Company
        • 7.2.5.1.4. Martindale Products and Specials
    • 7.2.6. Future Outlook
  • 7.3. Changzhou Delfu Technology
    • 7.3.1. Company Overview
    • 7.3.2. Financial Performance
    • 7.3.3. Product Portfolio
      • 7.3.3.1. Autoinjectors: Overview and Specifications
        • 7.3.3.1.1. Components of Delfu Autoinjectors
        • 7.3.3.1.2. Applications of Delfu Autoinjectors
        • 7.3.3.1.3. Features of Delfu Autoinjectors
        • 7.3.3.1.4. Advantages of Delfu Autoinjectors
        • 7.3.3.1.5. Specifications of Delfu Autoinjectors
      • 7.3.3.2. Autoinjectors: Product Details
        • 7.3.3.2.1. YZ-II 3mLCartridge Digital Dose Setting GF Autoinjector
        • 7.3.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
        • 7.3.3.2.3. DZ-IA Auto Injector Pen
        • 7.3.3.2.4. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
        • 7.3.3.2.5.YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
        • 7.3.3.2.6.YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
        • 7.3.3.2.7.YZ-II 3mL* 1u Auto inject Pen
        • 7.3.3.2.8.YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
        • 7.3.3.2.9.YZ-III Automatic Reusable Insulin Injection Pen
  • 7.4. DALI Medical Devices
    • 7.4.1. Company Overview
    • 7.4.2. Product Portfolio
      • 7.4.2.1. Autoinjectors
        • 7.4.2.1.1. SAN-L
        • 7.4.2.1.2. SAN-P
        • 7.4.2.1.3. SAN-DV
        • 7.4.2.1.4. SAN-DV Pro
  • 7.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
    • 7.5.1. Company Overview
    • 7.5.2. Product Portfolio
    • 7.5.3. Autoinjectors
      • 7.5.3.1. Flexi-Q Disposable Autoinjectors
        • 7.5.3.1.1. Flexi-Q PFS
        • 7.5.3.1.2. Flexi-Q HV
        • 7.5.3.1.3. Flexi -Q DV
      • 7.5.3.2. Flexi-Q Reusable Autoinjectors
        • 7.5.3.2.1. Flexi-Q mMU
        • 7.5.3.2.2. Flexi-Q eMU
      • 7.5.3.3. Comparison of Elcam Medical Autoinjectors
    • 7.5.4. Recent Developments
      • 7.5.4.1. Collaborations
    • 7.5.5. Future Outlook
  • 7.6. Meridian Medical Technologies
    • 7.6.1. Company Overview
    • 7.6.2. Product Portfolio
      • 7.6.2.1. Antidote Treatment Nerve Agent, Autoinjector (ATNAA): Atropine and Pralidoxime Chloride Injection
      • 7.6.2.2. AtroPen® Autoinjector: Atropine Injection
      • 7.6.2.3. Diazepam Autoinjector C-IV: Diazepam Injection
      • 7.6.2.4. DuoDote® Autoinjector: Atropine and Pralidoxime Chloride Injection
      • 7.6.2.5. Morphine Autoinjector C-II: Morphine Sulfate Injection
      • 7.6.2.6. Pralidoxime Chloride Autoinjector: Pralidoxime Chloride Injection
      • 7.6.2.7. Comparison of Meridian Medical Technologies Autoinjectors
      • 7.6.2.8. EpiPen®
      • 7.6.2.9. ALSUMA® / Sumatriptan Autoinjector
      • 7.6.2.10. Vanquix™ Autoinjector
      • 7.6.2.11. Investigational Midazolam Autoinjector
    • 7.6.3. Technology
    • 7.6.4. Future Outlook
  • 7.7. Owen Mumford
    • 7.7.1. Company Overview
    • 7.7.2. Product Portfolio
      • 7.7.2.1. Autoinjectors
        • 7.7.2.1.1. Autoject® Micro
        • 7.7.2.1.2. Autoject® 2
        • 7.7.2.1.3. Autoject® Mini
        • 7.7.2.1.4. Autoject Uni
        • 7.7.2.1.5. Autoject Multi
        • 7.7.2.1.6. Autoject® Flex
    • 7.7.3. Future Outlook
  • 7.8. Scandinavian Health Limited (SHL) Group
    • 7.8.1. Company Overview
    • 7.8.2. Product Portfolio
      • 7.8.2.1. Two-Step Disposable Autoinjectors
        • 7.8.2.1.1. Amber® (Pushclick™ Technology)
        • 7.8.2.1.2. Molly®
        • 7.8.2.1.3. Molly®RNS
        • 7.8.2.1.4. Molly® 2.25
        • 7.8.2.1.5. Molly® C
        • 7.8.2.1.6. NAISA® (Negasai™ Spring Technology)
        • 7.8.2.1.7. Comparison of SHL Two-Step Autoinjectors
      • 7.8.2.2. Three-Step Disposable Autoinjectors
        • 7.8.2.2.1. DAI®
        • 7.8.2.2.2. DAI®-RNS
        • 7.8.2.2.3. DAI®-R
        • 7.8.2.2.4. SDI-MIX®+NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
        • 7.8.2.2.5. VSDI-MIX™
        • 7.8.2.2.6. PSDI®
        • 7.8.2.2.7. Comparison of SHL Three-Step Autoinjectors
      • 7.8.2.3. PPI® Injector (Rotaject™ Pressure Release Technology)
    • 7.8.3. Recent Developments
    • 7.8.4. Collaborations
    • 7.8.5. Future Outlook
  • 7.9. Union Medico
    • 7.9.1. Company Overview
    • 7.9.2. Technology
    • 7.9.3. Product Portfolio
      • 7.9.3.1. 45° Autoinjector
        • 7.9.3.1.1. 45°/S Autoinjector
        • 7.9.3.1.2. 45°/M Autoinjector
        • 7.9.3.1.3. 45°/R Autoinjector
        • 7.9.3.1.4. Comparison of 45° Autoinjectors
      • 7.9.3.2. 90° Autoinjector
        • 7.9.3.2.1. 90°/S Autoinjector
        • 7.9.3.2.2. 90°/ M Autoinjector
        • 7.9.3.2.3. 90°/ XL Autoinjector
        • 7.9.3.2.4. SuperGrip™ Autoinjector
        • 7.9.3.2.5. Exclusive™ Autoinjector
        • 7.9.3.2.6. Comparison of 90° Autoinjectors
    • 7.9.4. Future Outlook
  • 7.10. Ypsomed
    • 7.10.1. Company Overview
    • 7.10.2. Financial Performance
    • 7.10.3. Product Portfolio
      • 7.10.3.1. Pen-Injectors
      • 7.10.3.2. Autoinjectors
        • 7.10.3.2.1.YpsoMate® and YpsoMate® 2.25
        • 7.10.3.2.2.VarioJect™
        • 7.10.3.2.3.YpsoMate® Smart
      • 7.10.3.3. Comparison of Ypsomed Autoinjectors
    • 7.10.4. Recent Developments
      • 7.10.4.1. Investment in Solothurn Facility
      • 7.10.4.2. Development of a New Generation of Injection and Infusion Systems
      • 7.10.4.3. Formative Study of Ypsomed Disposable Autoinjector: Results
      • 7.10.4.4. Plan to Increase Production Capacity
      • 7.10.4.5. Geographical Expansion
    • 7.10.5. Collaborations
      • 7.10.5.1. Thinfilm Electronics
      • 7.10.5.2. Tonghua Dongbao Pharmaceutical
      • 7.10.5.3. Terumo Corporation
      • 7.10.5.4. Hanmi Pharmaceutical
    • 7.10.6. Future Outlook

8. Emerging Players

  • 8.1. Chapter Overview
  • 8.2. Amedra Pharmaceuticals (Impax Laboratories)
    • 8.2.1. Company Overview
    • 8.2.2. Product Portfolio
      • 8.2.2.1. Adernaclick® Autoinjector
  • 8.3. Kaleo Pharma
    • 8.3.1. Company Overview
    • 8.3.2. Product Portfolio
      • 8.3.2.1. Auvi-Q® /Allerject
      • 8.3.2.2. EVZIO® Autoinjector
    • 8.3.3. Recent Developments
  • 8.4. Nuance Designs
    • 8.4.1. Company Overview
    • 8.4.2. Technology Overview
    • 8.4.3. Product Portfolio
      • 8.4.3.1. Fusion™ Autoinjector
      • 8.4.3.2. Quantum™ Autoinjector
  • 8.5. Oval Medical Technologies
    • 8.5.1. Company Overview
    • 8.5.2. Technology Overview
    • 8.5.3. Product Portfolio
    • 8.5.4. Recent Developments
  • 8.6. Xeris Pharmaceuticals
    • 8.6.1. Company Overview
    • 8.6.2. Technology Overview
    • 8.6.3. Product Portfolio
      • 8.6.3.1. G-Pen™ Autoinjector
      • 8.6.3.2. DiazePen™ Autoinjector
    • 8.6.4. Recent Developments
  • 8.7. Zion Clinical Pharmacy
    • 8.7.1. Company Overview
    • 8.7.2. Product Portfolio

9. Global Autoinjectors Market Forecast, 2016 - 2026

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Overall Autoinjectors: Market Size and Forecast
    • 9.3.1. Regional Market Size and Forecast: US, Europe, Asia Pacific and Rest of the World
    • 9.3.2. Overall Disposable Autoinjectors: Market Size and Forecast
    • 9.3.3. Overall Reusable Autoinjectors: Market Size and Forecast
    • 9.3.4. Overall Subcutaneous Autoinjectors: Market Size and Forecast
    • 9.3.5. Overall Intramuscular Autoinjectors: Market Size and Forecast
  • 9.4. Autoinjectors for Anaphylaxis: Market Size and Forecast
    • 9.4.1. Disposable Autoinjectors for Anaphylaxis: Market Size and Forecast
    • 9.4.2. Reusable Autoinjectors for Anaphylaxis: Market Size and Forecast
    • 9.4.3. Subcutaneous Autoinjectors for Anaphylaxis: Market Size and Forecast
    • 9.4.4. Intramuscular Autoinjectors for Anaphylaxis: Market Size and Forecast
  • 9.5. Autoinjectors for Multiple Sclerosis: Market Size and Forecast
    • 9.5.1. Disposable Autoinjectors for Multiple Sclerosis: Market Size and Forecast
    • 9.5.2. Reusable Autoinjectors for Multiple Sclerosis: Market Size and Forecast
    • 9.5.3. Subcutaneous Autoinjectors for Multiple Sclerosis: Market Size and Forecast
    • 9.5.4. Intramuscular Autoinjectors for Multiple Sclerosis: Market Size and Forecast
  • 9.6. Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
    • 9.6.1. Disposable Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
    • 9.6.2. Reusable Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
    • 9.6.3. Subcutaneous Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
    • 9.6.4. Intramuscular Autoinjectors for Rheumatoid Arthritis: Market Size and Forecast
  • 9.7. Autoinjectors for Migraine: Market Size and Forecast
    • 9.7.1. Disposable Autoinjectors for Migraine: Market Size and Forecast
    • 9.7.2. Reusable Autoinjectors for Migraine: Market Size and Forecast
    • 9.7.3. Subcutaneous Autoinjectors for Migraine: Market Size and Forecast
    • 9.7.4. Intramuscular Autoinjectors for Migraine: Market Size and Forecast
  • 9.8. Autoinjectors for Diabetes: Market Size and Forecast
    • 9.8.1. Disposable Autoinjectors for Diabetes: Market Size and Forecast
    • 9.8.2. Reusable Autoinjectors for Diabetes: Market Size and Forecast
    • 9.8.3. Subcutaneous Autoinjectors for Diabetes: Market Size and Forecast
    • 9.8.4. Intramuscular Autoinjectors for Diabetes: Market Size and Forecast
  • 9.9. Autoinjectors for Other Diseases: Market Size and Forecast
    • 9.9.1. Disposable Autoinjectors for Other Diseases: Market Size and Forecast
    • 9.9.2. Reusable Autoinjectors for Other Diseases: Market Size and Forecast
    • 9.9.3. Subcutaneous Autoinjectors for Other Diseases: Market Size and Forecast
    • 9.9.4. Intramuscular Autoinjectors for Other Diseases: Market Size and Forecast

10. Future Growth Opportunities

  • 10.1. Chapter Overview
  • 10.2. Life Cycle Management
  • 10.3. Growing Pipeline of Biologics and Biosimilars
  • 10.4. Emerging Target Indications for Autoinjectors
  • 10.5. Expansion/ Adoption in the Emerging Regions
  • 10.6. Specific Pockets of Growth

11. Interview Transcripts

  • 11.1. Chapter Overview
  • 11.2. Douglas Marenzi, Managing Director, PHC Injection Device Technologies
  • 11.3. Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical

12. Conclusion

  • 12.1. A Rapidly Growing Market Improving Patient Satisfaction
  • 12.2. Growing Pipeline of Biologics and Life Cycle Management are Amongst the Key Drivers of the Industry
  • 12.3. Several Combination Products Have Been Approved and Many are under Development
  • 12.4. Anaphylaxis Has Dominated the Market So Far; Multiple Sclerosis, Rheumatoid Arthritis, Migraine, Psoriasis and Diabetes Have Witnessed Rising Adoption
  • 12.5. Continued Growth in Disposable Devices; Increase in Demand for Reusable Devices
  • 12.6. Established Firms Leading the Market; New Entrants are Fostering Continued Innovation
  • 12.7. Next Generation Autoinjectors are on Their Way
  • 12.8. Despite Being Over Two Decades Old, Market is still Evolving with Significant Growth Expected in the Coming Decade
  • 12.9. Concluding Remarks

13. Appendix 1: Tabulated Data

14. Appendix 2: List of Companies and Organizations

List of Figures

  • Figure 2.1: Market Evolution: 2016, 2021, 2026(USD Million)
  • Figure 3.1: Types of Drug Delivery Systems
  • Figure 3.2: Types of Self-Injection Devices
  • Figure 3.3: Cartridge Based Autoinjectors v/s Prefilled Syringe Based Autoinjectors
  • Figure 3.4: Autoinjector: Components
  • Figure 3.5: Autoinjector: Classification
  • Figure 4.1: Dual Chamber Cartridge
  • Figure 4.2: Glass Prefilled Syringes: Advantages and Disadvantages
  • Figure 4.3: Plastic Prefilled Syringes: Advantages and Disadvantages
  • Figure 5.1: Autoinjectors: Distribution by Players
  • Figure 5.2: Autoinjectors: Distribution by Type of Primary Drug Container
  • Figure 5.3: Autoinjectors: Distribution by Usability
  • Figure 5.4: Autoinjectors: Distribution by Type of Dosage
  • Figure 5.5: Autoinjectors: Distribution by Route of Administration
  • Figure 5.6: Approved Combination Products: Distribution by Players
  • Figure 5.7: Approved Combination Products: Distribution by Indication
  • Figure 5.8: Approved Combination Products: Distribution by Type of Primary Drug Container
  • Figure 5.9: Approved Combination Products: Distribution by Usability
  • Figure 5.10: Approved Combination Products: Distribution by Route of Administration
  • Figure 5.11: Approved Combination Products: Distribution by Target Drug
  • Figure 5.12: Autoinjectors (Disposable): Product Competitiveness Analysis
  • Figure 5.13: Autoinjectors (Reusable): Product Competitiveness Analysis
  • Figure 6.1: Adrenaline / Epinephrine: History of Development
  • Figure 6.2: Adrenaline / Epinephrine: Historical Sales (USD Million), 2012-2014
  • Figure 6.3: Interferon beta-1a/Interferon beta-1b: History of Development
  • Figure 6.4: Interferon beta-1a: Historical Sales (USD Million), 2012-2014
  • Figure 6.5: Interferon beta-1b: Historical Sales (USD Million), 2012-2014
  • Figure 7.1: Bespak Sales (GBP Million), FY 2010-H1 2016
  • Figure 7.2: Bespak Injectables: Autoinjectors
  • Figure 7.3: Bespak Injectables: Syrina™ Autoinjectors
  • Figure 7.4: Delfu Autoinjectors: Components
  • Figure 7.5: Applications of Delfu Autoinjectors
  • Figure 7.6: DALI Medical Devices: Autoinjectors
  • Figure 7.7: SAN-L: Step Operations
  • Figure 7.8: SAN-P: Step Operations
  • Figure 7.9: SAN-DV: Step Operations
  • Figure 7.10: SAN-DV Pro: Step Operations
  • Figure 7.11: Elcam Medical: Products
  • Figure 7.12: Elcam Medical: Flexi-Q Autoinjectors
  • Figure 7.13: Flexi-Q PFS: Components
  • Figure 7.14: Flexi-Q PFS: Step Operations
  • Figure 7.15: Flexi-Q DV: Components
  • Figure 7.16: Flexi-Q DV: Step Operations
  • Figure 7.17: Flexi-Q mMU: Components
  • Figure 7.18: Flexi-Q eMU: Components
  • Figure 7.19: Flexi-Q mMU / Flexi-Q eMU: Step Operations
  • Figure 7.20: Meridian Medical Technologies: Autoinjectors
  • Figure 7.21: ATNAA: Step Operations
  • Figure 7.22: Diazepam Autoinjector C-IV: Step Operations
  • Figure 7.23: DuoDote® Autoinjector: Step Operations
  • Figure 7.24: Morphine Autoinjector: Step Operations
  • Figure 7.25: Pralidoxime Chloride Autoinjector: Step Operations
  • Figure 7.26: EpiPen®: Step Operations
  • Figure 7.27: ALSUMA® Autoinjector: Step Operations
  • Figure 7.28: Vanquix™ Autoinjector: Step Operations
  • Figure 7.29: Owen Mumford: Cartridge-Based Injection Pens
  • Figure 7.30: Owen Mumford: Autoinjectors
  • Figure 7.31: Autoject® Micro: Step Operations
  • Figure 7.32: Autoject® 2 Autoinjector: Step Operations
  • Figure 7.33: Autoject® Mini: Step Operations
  • Figure 7.34: Autoject® Uni: Step Operations
  • Figure 7.35: Autoject® Multi: Step Operations
  • Figure 7.36: Autoject® Flex: Step Operations
  • Figure 7.37: SHL Medical: Product Portfolio
  • Figure 7.38: SHL Medical: Prefilled Syringe Based Autoinjectors
  • Figure 7.39: SHL Medical: Cartridge Based Autoinjectors
  • Figure 7.40: SHL Medical: Two-Step Autoinjectors
  • Figure 7.41: SHL Medical Two-Step Autoinjectors: Step Operations
  • Figure 7.42: SHL Medical: Three-Step Autoinjectors
  • Figure 7.43: DAI®: Step Operations
  • Figure 7.44: DAI®-R: Step Operations
  • Figure 7.45: SDI-MIX®+NIT™: Step Operations
  • Figure 7.46: Union Medico: 45° Autoinjector Portfolio
  • Figure 7.47: Union Medico: Parts of 45°/R Autoinjector
  • Figure 7.48: Union Medico: Types of 45°/R Autoinjector
  • Figure 7.49: Union Medico: Types of 90° Autoinjectors
  • Figure 7.50: SuperGrip™ Autoinjector: Components
  • Figure 7.51: Exclusive™: Components
  • Figure 7.52: Ypsomed Sales (CHF Million), FY 2011- H1 2016
  • Figure 7.53: Ypsomed: Sales by Business Divisions, FY 2015(CHF Million, %)
  • Figure 7.54: Ypsomed: Sales by Business Divisions, H1 2016(CHF Million, %)
  • Figure 7.55: Ypsomed: Cartridge Based Pen-injectors
  • Figure 7.56: Ypsomed: Cartridge Based Dual Chamber Pen-injectors
  • Figure 7.57: Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors
  • Figure 7.58: YpsoMate®: Step Operations
  • Figure 7.59: VarioJect™: Step Operations
  • Figure 7.60: YpsoMate® Smart: Step Operations
  • Figure 8.1: XeriSol™ Technology: Working Mechanism
  • Figure 8.2: Trimix Autoinjector: Components
  • Figure 9.1: Overall Autoinjectors Market (Number of Units, Millions), 2016-2026
  • Figure 9.2: Overall Autoinjectors Market (USD Million), 2016-2026
  • Figure 9.3: Regional Autoinjectors Market (Number of Units, Millions), 2016-2026
  • Figure 9.4: Regional Autoinjectors Market (USD Million), 2016-2026
  • Figure 9.5: Overall Disposable Autoinjectors Market (Number of Units, Million), 2016-2026
  • Figure 9.6: Overall Disposable Autoinjectors Market (USD Million), 2016-2026
  • Figure 9.7: Overall Reusable Autoinjectors Market (Number of Units, Million), 2016-2026
  • Figure 9.8: Overall Reusable Autoinjectors Market (USD Million), 2016-2026
  • Figure 9.9: Overall Subcutaneous Autoinjectors Market (Number of Units, Million), 2016-2026
  • Figure 9.10: Overall Subcutaneous Autoinjectors Market (USD Million), 2016-2026
  • Figure 9.11: Overall Intramuscular Autoinjectors Market (Number of Units, Million), 2016-2026
  • Figure 9.12: Overall Intramuscular Autoinjectors Market (USD Million), 2016-2026
  • Figure 9.13: Autoinjectors for Anaphylaxis Market (Number of Units, Millions), 2016-2026
  • Figure 9.14: Autoinjectors for Anaphylaxis Market (USD Million), 2016-2026
  • Figure 9.15: Disposable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Figure 9.16: Disposable Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Figure 9.17: Reusable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Figure 9.18: Reusable Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Figure 9.19: Subcutaneous Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Figure 9.20: Subcutaneous Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Figure 9.21: Intramuscular Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Figure 9.22: Intramuscular Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Figure 9.23: Autoinjectors for Multiple Sclerosis Market (Number of Units, Million), 2016-2026
  • Figure 9.24: Autoinjectors for Multiple Sclerosis Market (USD Million), 2016-2026
  • Figure 9.25: Disposable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016-2026
  • Figure 9.26: Disposable Autoinjectors for Multiple Sclerosis (USD Million), 2016-2026
  • Figure 9.27: Reusable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016-2026
  • Figure 9.28: Reusable Autoinjectors for Multiple Sclerosis (USD Million), 2016-2026
  • Figure 9.29: Subcutaneous Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016-2026
  • Figure 9.30: Subcutaneous Autoinjectors for Multiple Sclerosis (USD Million), 2016-2026
  • Figure 9.31: Intramuscular Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016-2026
  • Figure 9.32: Intramuscular Autoinjectors for Multiple Sclerosis (USD Million), 2016-2026
  • Figure 9.33: Autoinjectors for Rheumatoid Arthritis Market (Number of Units, Million), 2016-2026
  • Figure 9.34: Autoinjectors for Rheumatoid Arthritis Market (USD Million), 2016-2026
  • Figure 9.35: Disposable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Figure 9.36: Disposable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Figure 9.37: Reusable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Figure 9.38: Reusable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Figure 9.39: Subcutaneous Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Figure 9.40: Subcutaneous Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Figure 9.41: Intramuscular Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Figure 9.42: Intramuscular Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Figure 9.43: Autoinjectors for Migraine Market (Number of Units, Million), 2016-2026
  • Figure 9.44: Autoinjectors for Migraine Market (USD Million), 2016-2026
  • Figure 9.45: Disposable Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Figure 9.46: Disposable Autoinjectors for Migraine (USD Million), 2016-2026
  • Figure 9.47: Reusable Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Figure 9.48: Reusable Autoinjectors for Migraine (USD Million), 2016-2026
  • Figure 9.49: Subcutaneous Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Figure 9.50: Subcutaneous Autoinjectors for Migraine (USD Million), 2016-2026
  • Figure 9.51: Intramuscular Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Figure 9.52: Intramuscular Autoinjectors for Migraine (USD Million), 2016-2026
  • Figure 9.53: Autoinjectors for Diabetes Market (Number of Units, Million), 2016-2026
  • Figure 9.54: Autoinjectors for Diabetes Market (USD Million), 2016-2026
  • Figure 9.55: Disposable Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Figure 9.56: Disposable Autoinjectors for Diabetes (USD Million), 2016-2026
  • Figure 9.57: Reusable Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Figure 9.58: Reusable Autoinjectors for Diabetes (USD Million), 2016-2026
  • Figure 9.59: Subcutaneous Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Figure 9.60: Subcutaneous Autoinjectors for Diabetes (USD Million), 2016-2026
  • Figure 9.61: Intramuscular Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Figure 9.62: Intramuscular Autoinjectors for Diabetes (USD Million), 2016-2026
  • Figure 9.63: Autoinjectors for Other Diseases Market (Number of Units, Million), 2016-2026
  • Figure 9.64: Autoinjectors for Other Diseases Market (USD Million), 2016-2026
  • Figure 9.65: Disposable Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Figure 9.66: Disposable Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Figure 9.67: Reusable Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Figure 9.68: Reusable Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Figure 9.69: Subcutaneous Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Figure 9.70: Subcutaneous Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Figure 9.71: Intramuscular Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Figure 9.72: Intramuscular Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Figure 10.1: Autoinjectors: Future Growth Opportunities
  • Figure 10.2: Numbers of Biologics Approved by the FDA, 2009-2015
  • Figure 12.1: Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (USD Million, #Millions)
  • Figure 12.2: Autoinjectors Market (2016, 2026): Distribution by Usability (USD Million, #Millions)
  • Figure 12.3: Autoinjectors Market (2016, 2026): Distribution by Route of Administration (USD Million, #Millions)

List of Tables

  • Table 3.1: Benefits of Autoinjectors
  • Table 4.1: Advantages of Glass as Barrel
  • Table 4.2: Companies Developing Cartridges
  • Table 4.3: Classification of Prefilled Syringes
  • Table 4.4: Glass Prefilled Syringes Available in the Market, 2015
  • Table 4.5: Plastic Prefilled Syringes Available in the Market, 2015
  • Table 5.1: List of Autoinjector Devices
  • Table 5.2: Autoinjectors: Distribution by Type of Dosage
  • Table 5.3: List of Approved Combination Products
  • Table 5.4: List of Pipeline Combination Products
  • Table 6.1: Drugs Available / Being Evaluated With Autoinjectors
  • Table 6.2: Adrenaline / Epinephrine: Commercially Available Autoinjectors
  • Table 6.3: Adrenaline /Epinephrine: Other Formulations
  • Table 6.4: Interferon beta-1a: Autoinjectors
  • Table 6.5: Interferon beta-1b: Autoinjectors
  • Table 6.6: Interferon-beta Drugs: Other Dosage Forms
  • Table 6.7: Marketed Molecules: Most Likely Candidates for Autoinjectors
  • Table 6.8: Marketed Molecules: Likely Candidates for Autoinjectors
  • Table 6.9: Marketed Molecules: Less Likely Candidates for Autoinjectors
  • Table 6.10: Pipeline Molecules: Most Likely Candidates for Autoinjectors
  • Table 6.11: Pipeline Molecules: Likely Candidates for Autoinjectors
  • Table 6.12: Pipeline Molecules: Less Likely Candidates for Autoinjectors
  • Table 7.1: Changzhou Delfu: Autoinjectors
  • Table 7.2: Delfu Autoinjectors: Specifications
  • Table 7.3: Elcam Medical: Comparison of Autoinjectors
  • Table 7.4: ATNAA: Constituents of Atropine Diluent (0.7mL)
  • Table 7.5: ATNAA: Constituents of Pralidoxime Chloride Diluent (2mL)
  • Table 7.6: AtroPen®: Comparison of AtroPen® Autoinjectors (Based on Dose Strengths)
  • Table 7.7: Diazepam Autoinjector C-IV: Constituents of Diazepam Diluent (1 mL)
  • Table 7.8: DuoDote® Autoinjector: Constituents of Atropine Diluent (0.7mL)
  • Table 7.9: DuoDote® Autoinjector: Constituents of Pralidoxime Chloride Diluent (2mL)
  • Table 7.10: Morphine Autoinjector C-II: Constituents of Diluent
  • Table 7.11: Pralidoxime Chloride Autoinjector: Constituents of Diluent (2mL)
  • Table 7.12: Meridian Medical Technologies: Comparison of Autoinjectors
  • Table 7.13: Owen Mumford: Comparison of AutoJect® 2 Variants
  • Table 7.14: Owen Mumford: Comparison of Autoject® 2 Variants Based on Size of the Needle
  • Table 7.15: Owen Mumford: Comparison of Autoject® Mini Variants Based on Size
  • Table 7.16: Owen Mumford: Autoject® Flex Variants (Features)
  • Table 7.17: Owen Mumford: Comparison of Autoinjectors
  • Table 7.18: SHL: Comparison of Two-Step Disposable Autoinjectors
  • Table 7.19: SHL: Comparison of Three-Step Disposable Autoinjectors
  • Table 7.20: Union Medico: Comparison of 45° Autoinjectors
  • Table 7.21: Union Medico: Comparison of 90° Autoinjectors
  • Table 7.22: Ypsomed: Comparison of Autoinjectors
  • Table 10.1: Emerging Indications for Autoinjectors
  • Table 13.1: Autoinjectors: Distribution by Players
  • Table 13.2: Autoinjectors: Distribution by Type of Primary Drug Container
  • Table 13.3: Autoinjectors: Distribution by Usability
  • Table 13.4: Autoinjectors: Distribution by Type of Dosage
  • Table 13.5: Autoinjectors: Distribution by Route of Administration
  • Table 13.6: Approved Combination Products: Distribution by Players
  • Table 13.7: Approved Combination Products: Distribution by Indication
  • Table 13.8: Approved Combination Products: Distribution by Type of Primary Drug Container
  • Table 13.9: Approved Combination Products: Distribution by Usability
  • Table 13.10: Approved Combination Products: Distribution by Route of Administration
  • Table 13.11: Autoinjectors: Distribution by Target Drug
  • Table 13.12: Adrenaline / Epinephrine: Historical Sales (USD Million), 2012-2014
  • Table 13.13: Interferon beta-1a: Historical Sales (USD Million), 2012-2014
  • Table 13.14: Interferon beta-1a: Historical Sales (USD Million), 2012-2014
  • Table 13.15: Bespak Sales (GBP Million), FY 2010-H1 2016
  • Table 13.16: Ypsomed Sales (CHF Million), FY 2011- H1 2016
  • Table 13.17: Ypsomed: Sales by Business Divisions (CHF Million, %), FY 2015
  • Table 13.18: Ypsomed: Sales by Business Divisions (CHF Million, %), H1 2016
  • Table 13.19: Overall Autoinjectors Market (Number of Units, Millions), 2016-2026
  • Table 13.20: Overall Autoinjectors Market (USD Million), 2016-2026
  • Table 13.21: Regional Autoinjectors Market (Number of Units, Millions), 2016-2026
  • Table 13.22: Regional Autoinjectors Market (USD Million), 2016-2026
  • Table 13.23: Overall Disposable Autoinjectors Market (Number of Units, Million), 2016-2026
  • Table 13.24: Overall Disposable Autoinjectors Market (USD Million), 2016-2026
  • Table 13.25: Overall Reusable Autoinjectors Market (Number of Units, Million), 2016-2026
  • Table 13.26: Overall Reusable Autoinjectors Market (USD Million), 2016-2026
  • Table 13.27: Overall Subcutaneous Autoinjectors Market (Number of Units, Million), 2016-2026
  • Table 13.28: Overall Subcutaneous Autoinjectors Market (USD Million), 2016-2026
  • Table 13.29: Overall Intramuscular Autoinjectors Market (Number of Units, Million), 2016-2026
  • Table 13.30: Overall Intramuscular Autoinjectors Market (USD Million), 2016-2026
  • Table 13.31: Autoinjectors for Anaphylaxis Market (Number of Units, Millions), 2016-2026
  • Table 13.32: Autoinjectors for Anaphylaxis Market (USD Million), 2016-2026
  • Table 13.33: Disposable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Table 13.34: Disposable Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Table 13.35: Reusable Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Table 13.36: Reusable Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Table 13.37: Subcutaneous Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Table 13.38: Subcutaneous Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Table 13.39: Intramuscular Autoinjectors for Anaphylaxis (Number of Units, Million), 2016-2026
  • Table 13.40: Intramuscular Autoinjectors for Anaphylaxis (USD Million), 2016-2026
  • Table 13.41: Autoinjectors for Multiple Sclerosis Market (Number of Units, Million), 2016-2026
  • Table 13.42: Autoinjectors for Multiple Sclerosis Market (USD Million), 2016-2026
  • Table 13.43: Disposable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016-2026
  • Table 13.44: Disposable Autoinjectors for Multiple Sclerosis (USD, Million), 2016-2026
  • Table 13.45: Reusable Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016-2026
  • Table 13.46: Reusable Autoinjectors for Multiple Sclerosis (USD Million), 2016-2026
  • Table 13.47: Subcutaneous Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016: -2026
  • Table 13.48: Subcutaneous Autoinjectors for Multiple Sclerosis (USD Million), 2016-2026
  • Table 13.49: Intramuscular Autoinjectors for Multiple Sclerosis (Number of Units, Million), 2016-2026
  • Table 13.50: Intramuscular Autoinjectors for Multiple Sclerosis (USD Million), 2016-2026
  • Table 13.51: Autoinjectors for Rheumatoid Arthritis Market (Number of Units, Million), 2016-2026
  • Table 13.52: Autoinjectors for Rheumatoid Arthritis Market (USD Million), 2016-2026
  • Table 13.53: Disposable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Table 13.54: Disposable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Table 13.55: Reusable Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Table 13.56: Reusable Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Table 13.57: Subcutaneous Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Table 13.58: Subcutaneous Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Table 13.59: Intramuscular Autoinjectors for Rheumatoid Arthritis (Number of Units, Million), 2016-2026
  • Table 13.60: Intramuscular Autoinjectors for Rheumatoid Arthritis (USD Million), 2016-2026
  • Table 13.61: Autoinjectors for Migraine Market (Number of Units, Million), 2016-2026
  • Table 13.62: Autoinjectors for Migraine Market (USD Million), 2016-2026
  • Table 13.63: Disposable Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Table 13.64: Disposable Autoinjectors for Migraine (USD Million), 2016-2026
  • Table 13.65: Reusable Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Table 13.66: Reusable Autoinjectors for Migraine (USD Million), 2016-2026
  • Table 13.67: Subcutaneous Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Table 13.68: Subcutaneous Autoinjectors for Migraine (USD Million), 2016-2026
  • Table 13.69: Intramuscular Autoinjectors for Migraine (Number of Units, Million), 2016-2026
  • Table 13.70: Intramuscular Autoinjectors for Migraine (USD Million), 2016-2026
  • Table 13.71: Autoinjectors for Diabetes Market (Number of Units, Million), 2016-2026
  • Table 13.72: Autoinjectors for Diabetes Market (USD Million), 2016-2026
  • Table 13.73: Disposable Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Table 13.74: Disposable Autoinjectors for Diabetes (USD Million), 2016-2026
  • Table 13.75: Reusable Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Table 13.76: Reusable Autoinjectors for Diabetes (USD Million), 2016-2026
  • Table 13.77: Subcutaneous Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Table 13.78: Subcutaneous Autoinjectors for Diabetes (USD Million), 2016-2026
  • Table 13.79: Intramuscular Autoinjectors for Diabetes (Number of Units, Million), 2016-2026
  • Table 13.80: Intramuscular Autoinjectors for Diabetes (USD Million), 2016-2026
  • Table 13.81: Autoinjectors for Other Diseases Market (Number of Units, Million), 2016-2026
  • Table 13.82: Autoinjectors for Other Diseases Market (USD Million), 2016-2026
  • Table 13.83: Disposable Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Table 13.84: Disposable Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Table 13.85: Reusable Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Table 13.86: Reusable Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Table 13.87: Subcutaneous Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Table 13.88: Subcutaneous Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Table 13.89: Intramuscular Autoinjectors for Other Diseases (Number of Units, Million), 2016-2026
  • Table 13.90: Intramuscular Autoinjectors for Other Diseases (USD Million), 2016-2026
  • Table 13.91: Numbers of Biologics Approved by the USFDA, 2009-2015
  • Table 13.92: Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (USD Million)
  • Table 13.93: Autoinjectors Market (2016, 2026): Distribution by Therapeutic Area (Number of Units)
  • Table 13.94: Autoinjectors Market (2016, 2026): Distribution by Usability (USD Million)
  • Table 13.95: Autoinjectors Market (2016, 2026): Distribution by Usability (Number of Units)
  • Table 13.96: Autoinjectors Market (2016, 2026): Distribution by Route of Administration (USD Million)
  • Table 13.97: Autoinjectors Market (2016, 2026): Distribution by Route of Administration (Number of Units)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3P Limited
  • 2. AbbVie
  • 3. Ablynx
  • 4. Aguettant
  • 5. ALK-Abelló A/S
  • 6. Allergy Therapeutics
  • 7. Alliance Healthcare
  • 8. Allozyne (Acquired by MedImmune)
  • 9. Amag Pharmaceuticals
  • 10. Amedra Pharmaceuticals (Acquired by Impax Laboratories)
  • 11. Amgen
  • 12. Antares Phama
  • 13. Aptar Pharma
  • 14. Arte Corporation
  • 15. Aventis Pharma
  • 16. Bang & Olufsen Medicom
  • 17. Bayer Healthcare
  • 18. Becton Dickinson & Co.
  • 19. Bespak
  • 20. Biogen Idec
  • 21. Bioprojet
  • 22. Boehringer Ingelheim
  • 23. Bristol-Myers Squibb
  • 24. Brunswick Biomedical Corporation
  • 25. Cambridge Capital Group
  • 26. Cambridge Consultants
  • 27. Celgene Corporation
  • 28. Central Texas Angel Network
  • 29. Changzhou Delfu Technology
  • 30. ChemProtect SK
  • 31. Chugai Pharmaceutical Co. Ltd
  • 32. CiToxLab
  • 33. Consort Medical
  • 34. Cytheris
  • 35. CytoDyn
  • 36. Daikyo Seiko
  • 37. DALI Medical Devices
  • 38. Disetronic
  • 39. Dr. Reddy's Laboratories
  • 40. Elcam Medical
  • 41. Eli Lilly
  • 42. EMD Serono
  • 43. Emergent Biosolutions
  • 44. Exsulin
  • 45. FFT Medical
  • 46. Future Injection Technologies
  • 47. Gerresheimer
  • 48. GlaxoSmithKline
  • 49. Global Pharma
  • 50. Globe Medical Tech
  • 51. Haselmeier AG
  • 52. Hemispherx Bioscience
  • 53. Hoffmann-La Roche
  • 54. Hospira
  • 55. Immune Response Biopharma
  • 56. Immunex
  • 57. Injectech
  • 58. Ionis Pharmaceuticals
  • 59. Janssen Biotech
  • 60. JHP Pharmaceuticals
  • 61. Jiangsu Delfu medical device
  • 62. Johnson & Johnson
  • 63. Kaleo (formerly known as Intelliject)
  • 64. King Pharmaceuticals
  • 65. Kisling AG
  • 66. Labrys Biologics (Acquired by Teva)
  • 67. Lincoln Medical (Acquired by Bioprojet Pharma)
  • 68. Lineage Therapeutics
  • 69. LyoGo
  • 70. medac GmbH
  • 71. Medac Pharma
  • 72. Medeca Pharma
  • 73. Medical Valley Alliance
  • 74. MedPro
  • 75. Merck
  • 76. Merck Serono
  • 77. Meridian Medical Technologies
  • 78. Merz Pharmaceuticals
  • 79. MSD Animal Health
  • 80. Mylan
  • 81. National Health Service
  • 82. Nemera
  • 83. Nipro Corporation (Acquired MGlas)
  • 84. Novartis
  • 85. Novo Nordisk
  • 86. Nuance Design
  • 87. Nuova Ompi
  • 88. Nuron Biotech
  • 89. Otsuka Pharmaceuticals
  • 90. Oval Medical Technologies
  • 91. Owen Mumford
  • 92. PA Consulting Group
  • 93. Palatin Technologies
  • 94. PDL BioPharma
  • 95. Pfizer
  • 96. Pharma-Pen
  • 97. PhaseBio Pharmaceuticals
  • 98. PHC Injection Device Technologies
  • 99. Plas-Tech Engineering
  • 100. Project Pharmaceutics
  • 101. Redmile Group
  • 102. Regeneron Pharmaceuticals
  • 103. Revolutions Medical
  • 104. Roselabs Bioscience
  • 105. Sabby Management
  • 106. Sanofi
  • 107. Sanofi Pasteur
  • 108. Santarus
  • 109. Scandinavian Health Limited Group
  • 110. School of Medicine at the University of Texas Health Science Center San Antonio
  • 111. SCHOTT AG
  • 112. Schreiner MediPharm
  • 113. Sciele Pharma (Now Known as Shionogi Pharma)
  • 114. Shandong Weigao Group
  • 115. SiliCycle
  • 116. SiO2 Medical Products
  • 117. SKINSORB
  • 118. Sumitomo Dainippon Pharma
  • 119. Sun Pharma
  • 120. Survival Technologies
  • 121. Taisei Kako
  • 122. Takeda
  • 123. Team Consulting
  • 124. Terumo Corporation
  • 125. Teva Pharma Industries
  • 126. Texas Diabetes Institute (TDI) of the University Health System
  • 127. The Cambridge Angels
  • 128. The McNair Group
  • 129. The Medical House (TMH)
  • 130. Tonghua Dongbao Pharmaceutical
  • 131. UCB
  • 132. Uman Pharma
  • 133. Unilife Corporation
  • 134. Union Medico
  • 135. US Medical Instruments
  • 136. US WorldMeds
  • 137. Valeant Pharmaceutical International
  • 138. Vetter Pharma
  • 139. West Pharmaceutical Services
  • 140. Windgap Medical
  • 141. Xeris Pharmaceuticals
  • 142. Ypsomed Delivery Systems
  • 143. Zion Clinical Pharmacy
Back to Top